Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.

摘要: Introduction: HER2 gene amplification or overexpression occurs in 15% to 25% of breast cancers and has implications for treatment prognosis. The most commonly used methods testing are fluorescence situ hybridization (FISH) immunohistochemistry. FISH is considered be the reference standard more accurately predicts response trastuzumab, but technically demanding, expensive, requires specialized equipment. In required eligible adjuvant with trastuzumab Australia. Bright-field an alternative uses a combination methodology peroxidase-mediated chromogenic substrate such as diaminobenzidine [chromogenic (CISH)] multimer technology coupled enzyme metallography [silver-enhanced (SISH)] create marker visible under bright-field microscopy. CISH was introduced into diagnostic Australia October 2006. SISH recent introduction repertoire. An evaluation performance assess patient outcome were performed using tissue microarrays. Materials Methods: Tissue microarrays constructed duplicate material from 593 patients invasive carcinoma assessed SISH. Gene American Society Clinical Oncology/College Pathologists guideline Australian Advisory Board criteria (single probe: diploid, 1 2.5 copies/nucleus; polysomy >2.5 4 equivocal, >4 6 low-level amplification, >6 10 copies/nucleus high-level >10 dual probe HER2/CHR17 ratio: nonamplified 2.2). Results: Results informative 337 cores comprising 230 samples. Concordance rates 96% single 95.5% Both correlated immunohistochemistry results cancer-specific survival. Conclusions: combines advantages automation microscopy facilitate workflow within laboratory, improves turnaround time, correlates outcome.